Business Wire

BOEHRINGER-INGELHEIM

Share
Boehringer Ingelheim announces European Medicines Agency’s filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis

Boehringer Ingelheim announced today that the company’s marketing authorization application (MAA) for the treatment of flares in generalized pustular psoriasis (GPP), has been validated and is now under evaluation with the European Medicines Agency (EMA).

“GPP is a rare, life-threatening neutrophilic skin disease characterized by painful, sterile pus-filled blisters, that can suddenly appear over the body,” said Dr. Janine Lamar, Global Spesolimab Lead at Boehringer Ingelheim. “Despite its name, GPP is very different to the more common plaque psoriasis. With no approved treatments in the EU for GPP flares, acceptance of the application for review of spesolimab brings us one step closer to providing a targeted treatment for people with this distressing, unpredictable and painful skin condition.”

GPP is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus).1,2,3 The inflammation can also affect other parts of the body and can lead to infections or other organ complications that may be life-threatening.

There is a high unmet need for treatments that can rapidly and completely resolve the symptoms of GPP flares. Flares greatly affect a person’s quality of life4 and can lead to hospitalization with life-threatening complications, such as heart failure, renal failure, sepsis and even death.5

The marketing authorization application was based on the 12 week Effisayil-1 trial; a multi-center, double-blind, randomized, placebo-controlled trial that evaluated efficacy, safety, and tolerability of spesolimab (single dose 900 mg spesolimab i.v., with the option of a 2nd dose if symptoms persisted on Day 8) in patients experiencing a GPP flare.6 The study demonstrated superiority over placebo in pustular clearance after one week of treatment.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/ema-filing-acceptance-and-validation-spesolimab

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NIQ Achieves Certification as Google Meridian Partner20.11.2025 12:00:00 CET | Press release

Certification strengthens NIQ’s position as a global leader in media outcomes measurement. NIQ, a leading consumer intelligence company, is proud to announce its certification as a Google Meridian partner, enabling NIQ to utilize Google’s open-source marketing mix models to measure marketing impact for advertisers. This achievement underscores NIQ’s commitment to delivering transparent and actionable outcome measurement solutions that help advertisers evaluate and optimize their marketing investments worldwide. Google's Meridian is an open-source Marketing Mix Model (MMM) designed to help businesses measure marketing effectiveness and optimize ad budgets across various media channels. By joining a select group of certified partners, NIQ is collaborating with Google to advance outcome measurement standards and introduce new innovations that complement NIQ’s proprietary MMM solution - helping make high-quality measurement more accessible to marketers everywhere. New Meridian innovations

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 202520.11.2025 12:00:00 CET | Press release

BRUKINSA now demonstrates best-in-class sustained efficacy and long-term benefit with a favorable safety profile over more than six years of follow-up data in treatment-naïve and R/R CLLFirst results from Phase 1/2 sonrotoclax monotherapy study will demonstrate notable speed and depth of clinical responses in patients with R/R MCL, a rare, aggressive cancerNew efficacy and safety data will highlight the benefits of potential first-in-class BTK degrader BGB-16673 in patients across multiple hematological malignancies BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, advances its vision to become the world’s leading oncology company with extensive new data from its differentiated hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, December 6-9. Nearly 50 abstracts have been accepted, including six oral presentations, featuring the company’s three transformative approved and investi

ZKB in Switzerland Completes ISO 20022 Migration Using Smartstream for Reconciliations20.11.2025 11:40:00 CET | Press release

Key Facts Zürcher Kantonalbank (ZKB) can now process ISO 20022 reporting messages ahead of the global SWIFT deadline, going live with Smartstream’s Corona MX solution as part of the Smart Reconciliations suite. The migration, executed in close collaboration with Smartstream and supported by ZKB’s ISO 20022 expertise, enhances the bank’s reconciliation capabilities, particularly for cash transactions across multi-account and currency operations. This strategic move strengthens ZKB’s commitment to innovation and compliance, enabling full payment lifecycle visibility and positioning the bank for future operational excellence. Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces, Zürcher Kantonalbank (ZKB), the largest cantonal bank in Switzerland, has successfully completed its ISO 20022 migration project for reporting messages, now live with Corona MX - part of the Smart Reconciliations solutions suite. This milestone

PUMA Partners with Logistics Reply to Accelerate AI-Driven Innovation in Warehousing20.11.2025 11:00:00 CET | Press release

Logistics Reply, the Reply group company specialising in innovative supply chain, has extended its collaboration with global sportswear brand PUMA to further optimise daily logistics operations and enhance user experience through the integration of GaliLEA, an AI-powered assistant built on the LEA Reply™ platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120676732/en/ Thanks to GaliLEA, PUMA has seen significant improvements in their daily use of the LEA Reply WMS, including increased user autonomy with less reliance on external support, faster management through quick data access and assisted ticket creation, real-time operational insights for better decision-making, and streamlined logistics workflows that enhance overall system interaction. Following the successful rollout of the LEA Reply™ Warehouse Management System (WMS) across four key distribution centers in Austria, South Africa, and India between 2022 and

euNetworks Appoints Nick Walden as Chief Revenue Officer20.11.2025 10:00:00 CET | Press release

euNetworks has today announced the appointment of Nick Walden as Chief Revenue Officer, effective 02 December 2025. Nick will be based in London and will drive all facets of euNetworks’ sales and commercial strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120550034/en/ Nick Walden - CRO of euNetworks Nick joins euNetworks following 30+ years in the Telecommunications industry, most recently having led the Global Sales function for Infinera (now Nokia) as Senior Vice President – Worldwide Sales. Prior to this, Nick served as Senior Vice President & Managing Director EMEA at Infinera following over a decade of experience in leadership roles at Ciena. “It’s an incredibly exciting time to be joining euNetworks, building on their strong growth and momentum as a critical bandwidth infrastructure provider across Europe. euNetworks’ relentless customer obsession aligns closely with my passion for delivering value for cust

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye